bullish
Pixium Vision - Restoring eyesight in advanced Dry-AMD
SUMMARY
Pixium Vision is developing Prima 2, a potentially breakthrough wireless bionic vision system (BVS) that generates electrical impulses at the retinal bipolar cell level to restore a form of central visual perception. It is on track to file to start a pivotal study in H220 for the treatment of advanced dry age-related macular degeneration (dry-AMD) involving geographic atrophy (GA). We obtain an enterprise value valuation of €105.9m, vs €98.0m previously. A rights offering is underway, expiring in July, which could raise €7.8m and increase the number of shares outstanding by 57.7%.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Pixium Vision - Restoring eyesight in advanced Dry-AMD22 Jun 2020
x